Taysha Gene Therapies Inc (TSHA NASDAQ) stock market data APIs
$3.9502
0.07(1.8%)
as of November 6, 2025
Try our APIs with
free plan!
Taysha Gene Therapies Inc Financial Data Overview
Price chart is built with
Anychart
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Prev. Close
3.9502
Open
4.0205
High
4.1031
Low
3.9289
52 wk Range
1.05-5.508
Market Cap
1 074 M
Shares Outstanding
274 M
Revenue
6 310 K
EPS
-0.08
Beta
1.028
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Taysha Gene Therapies Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Taysha Gene Therapies Inc data using free add-ons & libraries
Get Taysha Gene Therapies Inc Fundamental Data
Taysha Gene Therapies Inc Fundamental data includes:
- Net Revenue: 6 310 K
- EBITDA: -100 980 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.07
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Taysha Gene Therapies Inc News
New
Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights
Earnings Call Insights: Taysha Gene Therapies (TSHA) Q3 2025 MANAGEMENT VIEW * CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled by the strengt...
Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of the best NASDAQ stocks under $5 to buy now. On October 16, Taysha Gene Therapies announced that it had regained full global rights to its lead progra...
Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum
Taysha Gene Therapies Inc. (NASDAQ:TSHA) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential. On October 20, Raymond James initiated coverage on Taysha Gene Therapie...
Taysha Gene Therapies regains full rights to TSHA-102
designer491/iStock via Getty Images * Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) has announced that it has regained complete rights to its leading program, TSHA-102,...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
